BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 30622252)

  • 1. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.
    Balmus G; Pilger D; Coates J; Demir M; Sczaniecka-Clift M; Barros AC; Woods M; Fu B; Yang F; Chen E; Ostermaier M; Stankovic T; Ponstingl H; Herzog M; Yusa K; Martinez FM; Durant ST; Galanty Y; Beli P; Adams DJ; Bradley A; Metzakopian E; Forment JV; Jackson SP
    Nat Commun; 2019 Jan; 10(1):87. PubMed ID: 30622252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteome dynamics at broken replication forks reveal a distinct ATM-directed repair response suppressing DNA double-strand break ubiquitination.
    Nakamura K; Kustatscher G; Alabert C; Hödl M; Forne I; Völker-Albert M; Satpathy S; Beyer TE; Mailand N; Choudhary C; Imhof A; Rappsilber J; Groth A
    Mol Cell; 2021 Mar; 81(5):1084-1099.e6. PubMed ID: 33450211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.
    Badie S; Carlos AR; Folio C; Okamoto K; Bouwman P; Jonkers J; Tarsounas M
    EMBO J; 2015 Feb; 34(3):410-24. PubMed ID: 25582120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair.
    Chen CC; Kass EM; Yen WF; Ludwig T; Moynahan ME; Chaudhuri J; Jasin M
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7665-7670. PubMed ID: 28659469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
    Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
    Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATM antagonizes NHEJ proteins assembly and DNA-ends synapsis at single-ended DNA double strand breaks.
    Britton S; Chanut P; Delteil C; Barboule N; Frit P; Calsou P
    Nucleic Acids Res; 2020 Sep; 48(17):9710-9723. PubMed ID: 32890395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
    Dibitetto D; Liptay M; Vivalda F; Dogan H; Gogola E; González Fernández M; Duarte A; Schmid JA; Decollogny M; Francica P; Przetocka S; Durant ST; Forment JV; Klebic I; Siffert M; de Bruijn R; Kousholt AN; Marti NA; Dettwiler M; Sørensen CS; Tille JC; Undurraga M; Labidi-Galy I; Lopes M; Sartori AA; Jonkers J; Rottenberg S
    Nat Commun; 2024 May; 15(1):4430. PubMed ID: 38789420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier.
    Willis NA; Panday A; Duffey EE; Scully R
    PLoS Genet; 2018 Jul; 14(7):e1007486. PubMed ID: 30024881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
    Löser DA; Shibata A; Shibata AK; Woodbine LJ; Jeggo PA; Chalmers AJ
    Mol Cancer Ther; 2010 Jun; 9(6):1775-87. PubMed ID: 20530711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
    Xu G; Chapman JR; Brandsma I; Yuan J; Mistrik M; Bouwman P; Bartkova J; Gogola E; Warmerdam D; Barazas M; Jaspers JE; Watanabe K; Pieterse M; Kersbergen A; Sol W; Celie PHN; Schouten PC; van den Broek B; Salman A; Nieuwland M; de Rink I; de Ronde J; Jalink K; Boulton SJ; Chen J; van Gent DC; Bartek J; Jonkers J; Borst P; Rottenberg S
    Nature; 2015 May; 521(7553):541-544. PubMed ID: 25799992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
    Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
    Zander SA; Kersbergen A; van der Burg E; de Water N; van Tellingen O; Gunnarsdottir S; Jaspers JE; Pajic M; Nygren AO; Jonkers J; Borst P; Rottenberg S
    Cancer Res; 2010 Feb; 70(4):1700-10. PubMed ID: 20145144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    Becker JR; Cuella-Martin R; Barazas M; Liu R; Oliveira C; Oliver AW; Bilham K; Holt AB; Blackford AN; Heierhorst J; Jonkers J; Rottenberg S; Chapman JR
    Nat Commun; 2018 Dec; 9(1):5406. PubMed ID: 30559443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ING3 is required for ATM signaling and DNA repair in response to DNA double strand breaks.
    Mouche A; Archambeau J; Ricordel C; Chaillot L; Bigot N; Guillaudeux T; Grenon M; Pedeux R
    Cell Death Differ; 2019 Nov; 26(11):2344-2357. PubMed ID: 30804473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
    Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SV40 utilizes ATM kinase activity to prevent non-homologous end joining of broken viral DNA replication products.
    Sowd GA; Mody D; Eggold J; Cortez D; Friedman KL; Fanning E
    PLoS Pathog; 2014 Dec; 10(12):e1004536. PubMed ID: 25474690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
    Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
    Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.